Últimas noticias sobre Golden Sun Health (NASDAQ:GSUN) Bolsa

Golden Sun Education Gr

Golden Sun Health Technology Group Ltd is engaged in the provision of education and management services in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistic and consulting services. The company operates in two segments; Education segment and the Wellness segment. Majority of the revenue is generated from the Education segment which offers foreign language tutorial services and other education training management services in China. The wellness segment offers wellness service and related products.

Golden Sun Health Technology Group Limited - Class A Ordinary Shares

Golden Sun Health Technology Group Ltd

Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.08) by 175 percent. This is a 26.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $64.52 million which missed the analyst consensus estimate of $68.61 million by 5.97 percent. This is a 2.60 percent decrease over sales of $66.24 million the same period last year.

Earnings

Earnings Misses

News

FLNT

Fluent Q3 Adj $(0.22) Misses $(0.08) Estimate, Sales $64.52M Miss $68.61M Estimate

If you've ever regretted eating that second gummy because the first one took forever to kick in, you're not alone. From unpredictable highs to hours of couch lock, the edible experience can be a minefield of bad trips. But Azuca is on a mission to change all that.
With a revolutionary whole-plant infusion process, Azuca's food-tech innovation standardizes the high. No solvents, no distillates—just a fast-acting, full-spectrum experience that finally delivers on the promise of predictable, enjoyable edibles.&nbsp;
In an exclusive interview with Benzinga Cannabis, CEO Kim Sanchez Rael shared how this innovation isn't just a win for consumers, it's a game changer for cannabis investors and edibles brands looking to stand out in a crowded market. 
"We've eliminated the typical pitfalls of the edibles segment," said Rael. "Our process offers a cleaner, more efficient path to product differentiation and profitability, all while delivering a superior experience to the end consumer."
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">A New Chapter In Edibles: Whole-Plant Infusion Without Extractions</h3>
One of the most significant breakthroughs from Azuca is its ability to <a href="https://feeds2.benzinga.com/markets/cannabis/24/04/38473652/inside-gr-ns-marijuana-edibles-factory-what-can-we-learn-about-choco-nomics-and-multi-state-expa">create edibles</a> using the entire cannabis flower without relying on extractions like distillate or resin. Traditional edible production involves extracting THC from the cannabis plant, often using solvents.&nbsp;
Meanwhile,<a href="https://www.benzinga.com/markets/cannabis/24/04/38093020/exclusive-why-wait-azuca-obx-speed-up-cannabis-access"> Azuca </a>utilizes the entire flower, delivering what Rael called a true "entourage effect" in an edible format. "We've made it possible to infuse edibles directly with cannabis flower, bypassing the need for any extraction. This means consumers get the full spectrum of the plant's compounds—<a href="https://www.benzinga.com/general/biotech/24/05/38626097/why-does-tangie-smell">cannabinoids, terpenes, and flavonoids</a>—in a consistent format. It's the closest experience to smoking the plant but without the need to inhale."
<h3 class="wp-block-heading">Ending The Bad Trip: Predictable Highs</h3>
Traditional<a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40520617/detroits-first-cannabis-bakery-and-cafe-opens-soon-thc-cbd-infused-delights-await"> edibles</a> can take anywhere from 1 to 2 hours to kick in, leading many users to consume more than they should in frustration. The slow metabolization of THC in the liver can also produce a different, often more intense form of THC, which can result in a heavier, sedative effect—what the industry colloquially calls "couch lock."
Azuca's proprietary technology addresses this problem head-on. By encapsulating cannabis oil molecules in a starch-based shell, Azuca ensures that the cannabinoids are transformed into water-soluble compounds.&nbsp;
The encapsulation process allows the active ingredients to be absorbed rapidly in the mouth and upper digestive tract, bypassing the liver's delayed metabolization.
"Our technology delivers onset times as quick as 5 to 15 minutes," explained Rael. "This fast absorption not only prevents overconsumption but also offers a more predictable and sessionable experience, similar to smoking but in an <a href="https://feeds2.benzinga.com/markets/cannabis/24/10/41388261/revolutionizing-cannabis-edibles-ascends-new-thc-cannabinoid-blends-now-available-in-this-east-c">edible form</a>."
The encapsulation process also preserves the chemical integrity of the<a href="https://www.benzinga.com/markets/cannabis/23/12/36394288/cannabis-2024-experts-weigh-in-what-to-expect-from-dc-and-business-outlook-exciting-point-in-tim"> cannabinoids</a>, meaning that consumers experience THC in its Delta-9 form rather than the more intense 11-hydroxy-THC.&nbsp;
"We've effectively standardized the high," said Rael. "Gone are the days of nausea, anxiety, and unpredictable effects. Our products deliver a consistent, uplifting experience every time." While Azuca's technology aims to deliver a standardized, predictable experience,<a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40121179/cannabis-edibles-gone-wrong-high-flyers-door-forcing-drama-and-assault-force-emergency-landing"> individual responses can still vary</a> based on dosage, personal tolerance and other factors.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41948483/give-me-a-break-new-york-times-says-actor-jim-belushi-as-he-defends-cannabis-criticizes-big-pharma-food-industry"> &#8216;Give Me A Break, New York Times,&#8217; Says Actor Jim Belushi As He Defends Cannabis, Criticizes Big Pharma, Food Industry</a>
<h3 class="wp-block-heading">Starch Encapsulation: The Vanguard Of Food-Tech In Cannabis</h3>
Azuca's innovations are rooted in cutting-edge food technology, specifically the use of modified starches for encapsulating oil-based cannabinoids. Traditional methods of infusing <a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40471578/mike-tysons-new-line-of-weed-gummies-now-available-in-colorado-heres-where-to-find-them-and-win-">edibles with THC</a> involve the use of sticky, viscous distillate, which can lead to significant waste and degradation of potency during the cooking process. Distillates are prone to transfer loss, cannabis oil sticking to mixing equipment, and oxidation from exposure to heat.
Azuca's encapsulation technique solves these issues. The proprietary starch coating not only makes the cannabinoids water-friendly but also prevents them from sticking to equipment, reducing waste.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="731" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-731x1024.jpg" alt="" class="wp-image-646421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-731x1024.jpg 731w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-214x300.jpg 214w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew-768x1076.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13164839/Kim-Sanchez-Rael-headshot-cred_-Kim-Jew.jpg 771w" sizes="(max-width: 731px) 100vw, 731px" /><figcaption class="wp-element-caption">Kim Sanchez Rael &#8211; headshot-cred_ Kim Jew</figcaption></figure>
According to Rael, the process reduces active ingredient loss by up to 20% during manufacturing, translating to significant cost savings for producers.
"Our starch encapsulation process is a game changer for the industry," Rael noted. "It protects the cannabinoids from degradation, ensuring potency, and allows for seamless integration into any <a href="https://feeds2.benzinga.com/markets/cannabis/24/08/40225540/summer-sizzles-with-thc-infused-beverages-market-report-reveals-top-selling-weed-drinks-in-u-s">edible product</a> without the need for additional extraction or emulsification equipment."
<h3 class="wp-block-heading">Scale And Market Reach</h3>
Azuca's business model is built on licensing its technology to cannabis brands and manufacturers. This approach has allowed the company to quickly <a href="https://feeds2.benzinga.com/markets/cannabis/24/06/39538627/from-local-startup-to-cannabis-edibles-powerhouse-cameron-saner-on-pushing-kosmik-brands-to-infi">scale and penetrate multiple markets</a> across the U.S. and Canada. The process is straightforward: Azuca supplies its proprietary Activator, a non-infused precursor, which manufacturers can easily mix with their cannabis input—whether it's distillate, live resin, or whole flower.
"Our model is designed to be scalable for any size operation," she said. "We have over 100 licensing agreements and have infused close to 2 billion milligrams of cannabinoids since our launch."
The Activator is available in different formulations tailored for various product types, including gummies, beverages, and chocolates. "We've made it easy for our partners to integrate our technology into their existing processes, without the need for heavy equipment or extensive training," Rael explained.
Read Also: <a href="https://www.benzinga.com/news/24/09/40941818/how-this-cheese-aging-tech-is-boosting-profits-for-cannabis-growers-stop-throwing-cheddar-out-the-do">How This Cheese-Aging Tech Is Boosting Profits For Cannabis Growers: Stop Throwing Cheddar Out The Door</a>
<h3 class="wp-block-heading">Financial Impact: Reduced Waste, Increased Profit Margins</h3>
Azuca's technology offers significant financial advantages for manufacturers. The reduction in waste during production not only improves efficiency but also boosts profitability. Products made with Azuca's technology often command a premium price in the marketplace.&nbsp;
"Consumers are willing to pay more for a product that offers a predictable, high-quality experience," said Rael. "We've seen premium pricing of 20% or more for fast-acting edibles, and up to a 50% premium for products that combine fast onset with functional effects like sleep or relaxation."
<h3 class="wp-block-heading">Beyond The Bud</h3>
While Azuca is focused on the cannabis industry, Rael sees potential applications for their encapsulation technology in other sectors, such as nutraceuticals. "This is fundamentally a substance delivery system. We're taking molecules that are difficult to metabolize and making them easy for the body to absorb. The same principles could apply to vitamins, supplements, and other active ingredients outside of cannabis."
By eliminating the need for extractions and delivering a fast, predictable, and enjoyable experience, Azuca is paving the way for a new generation of cannabis edibles.
"We're driven by innovation," Rael concluded. "Our mission is to raise the bar for what edibles can be and to provide a better experience for both consumers and manufacturers alike. This is just the beginning."
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40972472/x-rays-microwaves-and-now-what-this-company-freezes-weed-at-320-f-to-kill-mold-and-save-a-ton">X-Rays, Microwaves, And Now What? This Company Freezes Weed At -320°F To Kill Mold And Save A Ton</a>

Cannabis

Exclusives

Interview

Was The Whole Gummy Too Much? Azuca Solves The Cannabis Edibles Problem With Food-Tech

Earnings Beats

ALRN

Aileron Therapeutics Q3 EPS $(0.27) Beats $(0.41) Estimate

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

Price Target

Analyst Ratings

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Kidpik (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIK#NASDAQ">PIK</a>) reported quarterly losses of $(0.45) per share. This is a 62.5 percent increase over losses of $(1.20) per share from the same period last year. The company reported $1.00 million in sales this quarter. This is a 70.49 percent decrease over sales of $3.39 million the same period last year.

Kidpik Q3 EPS $(0.45) Up From $(1.20) YoY, Sales $1.00M Down From $3.39M YoY

TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate.

TMC Metals Q3 2024 GAAP EPS $(0.06), Inline

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported $426.42 thousand in sales this quarter. This is a 50.02 percent decrease over sales of $853.10 thousand the same period last year.

HCWB

HCW Biologics Q3 Sales $426.42K Down From $853.10K YoY

AGFY

Agrify Q3 EPS $(17.31) Up From $(19.02) YoY; Revenue $1.934M Down From $3.139M YoY

Trading Ideas

BRK/A

POOL

SIRI

Berkshire Hathaway 13F Shows Added New Stake In Sirius XM Holdings With 105.16M Shares, Worth $2.49B; Added New Stake In Domino's Pizza With 1.28M Shares, Worth $549.4M; Added New Stake In Pool Corp With 404,057 Shares, Worth $152.2M

Berkshire Hathaway 13F Shows Increased Stake In American Express By 17% To 151.6M Shares, Now Worth $41.1B; Increased Stake In Kroger By 15% To 50M Shares, Worth $2.87B; Increased Stake In DaVita By 18%, Now Valued At $5.92B; Increased Stake In Moody's Corp By 13% To 24.67M Shares, Now Worth $11.71B

ROLR

High Roller Technologies Unaudited Q3 Revenue $7.52M Up From $5.80M QoQ

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

CHTR

Berkshire Hathaway 13F Shows Reduced Stake In Bank Of America By 23% To 797.7M Shares, Worth $31.7B; Reduced Stake In Charter Communications By 26% To 2.82M Shares, Worth $914.5M; Reduced Stake In Nu Holdings By 19% To 86.4M Shares, Worth $1.18B; Reduced Stake In Occidental Petroleum By 18%, Now Valued At $13.16B

Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.25 by 24 percent. The company reported quarterly sales of $33.391 million which beat the analyst consensus estimate of $31.750 million by 5.17 percent. This is a 33.02 percent decrease over sales of $49.854 million the same period last year.

CWCO

Consolidated Water Co Q3 2024 GAAP EPS $0.31 Beats $0.25 Estimate, Sales $33.391M Beat $31.750M Estimate

NMHI

Nature's Miracle Holding Q3 EPS $(0.09), Sales $3.05M Up From $2.69M YoY

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) with a Buy and maintains $9 price target.

KAPA

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

<a href="https://truthsocial.com/@realDonaldTrump/113483513301208163" title="https://truthsocial.com/@realDonaldTrump/113483513301208163">https://truthsocial.com/@realDonaldTrump/113483513301208163</a>

Macro Notification

Politics

General

CORRECTION: Trump Picks Jay Clayton For U.S. Attorney For The Southern District Of New York

Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares are up 23.4% to $89.54 in November following the company's <a href="https://www.benzinga.com/news/earnings/24/11/41754359/astera-labs-stock-is-ripping-higher-today-whats-going-on">impressive third-quarter earnings</a> beat Wall Street expectations, reinforcing its role as a critical player in AI infrastructure. 
What To Know: Astera reported earnings of 23 cents per share, exceeding the estimated 17 cents, alongside revenue of $113.1 million, up 206% year-over-year and well above analyst forecasts of $97.4 million. 
CEO Jitendra Mohan highlighted that the company achieved its fifth consecutive quarter of record-breaking revenue, with sales rising 47% from the previous quarter, driven by new growth in AI connectivity solutions.
Astera's latest product, the Scorpio Smart Fabric Switch, is central to its strategy. These switches are designed to enhance data transfer speeds between GPUs, CPUs and storage devices, addressing critical needs in AI data centers where performance demands are skyrocketing.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What Else: The company's strong performance and promising product pipeline prompted multiple analysts to raise their price targets.
JPMorgan increased its target to $110 per share, while Deutsche Bank, Barclays and others <a href="https://www.benzinga.com/quote/ALAB/analyst-ratings">made upward revisions</a>. 
Astera's revenue forecast for the fourth quarter of $126–$130 million, alongside expected earnings of 25 cents to 26 cents per share, has added momentum to investor enthusiasm.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
<h2 class="wp-block-heading">How To Buy ALAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Astera Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALAB has a 52-week high of $100.09 and a 52-week low of $36.22.

ALAB

Astera Labs (ALAB) Stock Is Up 23% This Month: What's Going On?

CV Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>), a <a href="http://benzinga.com/topic/hemp">hemp</a>-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">$4 million in Q2 2024</a>.</li>
<li>Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.</li>
<li>Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.</li>
<li>Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.</li>
</ul>
<h3 class="wp-block-heading">New Product Lines Boost Growth</h3>
Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, <a href="https://www.benzinga.com/markets/cannabis/24/03/37988133/hemp-focused-wellness-co-moves-closer-to-profitability-reports-flat-2023-revenue-increase-in-gro">inching closer</a> to cash flow break-even.
Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Management Commentary</h3>
CEO Joseph Dowling highlighted the <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">steady core revenue</a> in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. &#8220;Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,&#8221; Dowling <a href="https://www.prnewswire.com/news-releases/cv-sciences-inc-reports-third-quarter-2024-financial-results-302305079.html">said</a> in a press release.
Read Also: <a href="https://www.benzinga.com/24/11/41971875/cbd-pioneer-charlottes-web-narrows-loss-in-q3-focuses-on-long-term-growth-amid-challenging-cannabis-industry-environment">CBD Pioneer Charlotte&#8217;s Web Narrows Loss In Q3, Focuses On Long-Term Growth</a>
"We look forward to organically grow our business and pursue additional M&amp;A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.
<h3 class="wp-block-heading">CV Sciences Holds Top Market Spot</h3>
In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from Streeterville, aimed at fueling operational and product expansion.
CVSI Price Action CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a></li>
</ul>

CVSI

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

RIVN

iShares Trust Barclays 20+ Year Treasury Bond Fund

Soros Fund Management 13F Shows Exited Position In SPDR S&P 500 ETF, Previously Holding 450,000 Shares; Exited Stake In Rivian Automotive Call Options, Previously Holding 5,450,000 Shares; Exited Put Position In Ishares 20+ Year Treasury Bond ETF, Previously Holding 360,000 Shares; Exited Stake In Westrock Co, Previously Holding 3,342,953 Shares;  Exited Stake In Livongo Health Convertible Notes, Previously Holding $45M In Principal

Golden Sun Education Group Limited Class A (GSUN) has released an update. Golden Sun Health Technology Group Limited, known for its educational ser...

Golden Sun Back in Compliance with Nasdaq

Beauty Health and Natural Grocers among Consumer Staples movers

B&G Foods and Herbalife among Consumer Staples movers

Beyond Meat and SNDL among Consumer Staples movers

VFF and XXII among Consumer Staples movers

Gaotu Techedu and Grocery Outlet among Consumer Staples movers

Celsius and Mynd.ai among Consumer Staples movers

Golden Sun Education Group Limited Class A (GSUN) has released an update. Golden Sun Education Group Limited reports a noticeable decrease in total...

Golden Sun Education Group's Financial Update

Golden Sun Education Group Limited Class A (GSUN) has released an update. Golden Sun Health Technology Group Limited is set to hold its 2024 Annual...

Golden Sun Group Schedules 2024 Shareholder Meeting

Golden Sun Education Group Limited Class A (GSUN) has released an update. Golden Sun Health Technology Group Limited recently concluded its 2024 an...

Golden Sun Education Group's Key 2024 Meeting Outcomes

AGRI

AGRO

AMBO

BRCC

BRLS

BSFC

BTTR

BYND

CELH

CLEU

EAST

EDBL

GOTU

GROV

GSUN

HAIN

HIMS

ISPR

KAVL

LWAY

MYND

NGVC

SHOT

SISI

SKIN

SMFL

SNDL

TCTM

WAFU

XXII

Press Releases

Golden Sun Education Group Limited Schedules Press Conference to Announce Strategic Transformation on January 26, 2024, in Wenzhou, Zhejiang Province

Golden Sun Health Technology Group Limited Announces Strategic Transition into the Wellness Industry in China

Golden Sun Health Technology Group Limited Announces Receipt of Nasdaq Delisting Determination and Plan to Appeal

Golden Sun Health Technology Group Limited Announces 1-for-10 Share Consolidation

Golden Sun Health Technology Group Limited Regains Compliance with Nasdaq Continued Listing Requirement

Golden Sun Health Technology Group Limited Announces Joint Venture to Enter the Cultural Tourism Market

Golden Sun Health Technology Group Limited Announces Annual General Meeting Results

Color Star Technology Co., Ltd. - Class A Ordinary Shares

Color Star Tech

Ambow Education Holding Ltd. American Depository Shares (each representing twenty (20) Class A Ordinary Shares)

Ambow Education Holding

Amesite

Skillful Craftsman Education Technology Limited - Ordinary Share

Skillful Craftsman

EpicQuest Education Group International Limited - Common Stock

EpicQuest Education Group

Four Seasons Education (Cayman) Inc. American Depositary Shares, each ADS representing 10 ordinary shares

Comments

Golden Sun Health

Noticias

Últimas noticias sobre Golden Sun Health (NASDAQ:GSUN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL